292 related articles for article (PubMed ID: 30929824)
1. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
2. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates: present and future.
Beck A; Reichert JM
MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
6. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
8. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Goldenberg DM; Sharkey RM
Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the folate receptor α in oncology.
Scaranti M; Cojocaru E; Banerjee S; Banerji U
Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
[TBL] [Abstract][Full Text] [Related]
10. Update on antibody-drug conjugates in breast cancer.
Hugo HS
Clin Adv Hematol Oncol; 2021 Mar; 19(3):148-151. PubMed ID: 33739962
[No Abstract] [Full Text] [Related]
11. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
Lazzerini L; Jöhrens K; Sehouli J; Cichon G
Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
[TBL] [Abstract][Full Text] [Related]
12. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
14. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
15. Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A; Goetsch L; Dumontet C; Corvaïa N
Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
17. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
